Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.34 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23761110 | 1.00 | FABP3 (0.43) | FABP3PLA2G2CLPAR3LPAR1ENPP2 | |
| SCHEMBL20111594 | 1.00 | FABP3 (0.43) | FABP3PLA2G2CLPAR3LPAR1ENPP2 | |
| SCHEMBL29451071 | 1.00 | FABP3 (0.43) | FABP3PLA2G2CLPAR3LPAR1ENPP2 | |
| SCHEMBL21523585 | 0.87 | FABP3 (0.59) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL14346443 | 0.87 | FABP3 (0.59) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL21370526 | 0.87 | FABP3 (0.41) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL234632 | 0.86 | P2RY10 (0.44) | — | |
| SCHEMBL26236290 | 0.86 | LPAR3 (0.39) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL23015250 | 0.86 | P2RY10 (0.44) | — | |
| SCHEMBL14369568 | 0.85 | FABP3 (0.40) | FABP3LPAR3LPAR1ENPP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3714 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079802-A | Cationic lipids and compositions thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260131021-A1 | LIPID NANOPARTICLE-BASED DRUG DELIVERY SYSTEM USING RECOMBINANT PROTAMINE AND METHOD FOR PREPARING SAME | MOOGENE MEDI CO., LTD. (KR) | 2026-05-14 | — | — | US | claimed |
| US-20260125681-A1 | DOUBLE-STRANDED RNAi AGENTS FOR TARGETING AND REGULATING HBV GENE EXPRESSION, AND A USE THEREOF | HANGZHOU TIANLONG PHARMACEUTICAL CO., LTD. (CN) | 2026-05-07 | — | — | US | claimed |
| EP-4736848-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CATIONIC LIPID AND USE THEREOF | Shanghai Regenelead Therapies Co., Ltd. (CN) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090423-A1 | UNIVERSAL LNP COMPOSITIONS | PRIME MEDICINE, INC (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090505-A1 | FLUOROPYRIMIDINE PARTICLES FOR THE TREATMENT OF CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090328-A1 | WNT7a MRNA LIPID NANOPARTICLES FOR THERAPEUTIC USES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | claimed |
| US-20260108473-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO (US) | 2026-04-23 | — | — | US | claimed |
| WO-2005116270-A2 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHOD OF USE | VICAL INCORPORATED (US) | 2005-12-08 | — | — | WO | claimed |
| WO-2005105152-A2 | LIPIDS, LIPID COMPLEXES AND USE THEREOF | ATUGEN AG (DE) | 2005-11-10 | — | — | WO | claimed |
| EP-1575505-A2 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST BACILLUS ANTHRACIS INFECTION | Vical Incorporated (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1575505-A3 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST BACILLUS ANTHRACIS INFECTION | Vical Incorporated (US) | 2005-09-01 | — | — | EP | claimed |
| US-20040234586-A1 | Compositions and methods for enhancing nucleic acid transfer into cells | UNIVERSITE DE MONTREAL (CA) | 2004-11-25 | — | — | US | claimed |
| EP-1165140-B1 | ADJUVANT COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES TO POLYNUCLEOTIDE-BASED VACCINES | VICAL INC (US) | 2004-08-04 | — | — | EP | claimed |
| WO-2004024067-A2 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST BACILLUS ANTHRACIS INFECTION | VICAL INCORPORATED (US) | 2004-03-25 | — | — | WO | claimed |
| US-6586409-B1 | N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(-9-tetradeceneyloxy)-1 -propanaminium salt; cytofectin and lipid mixture | VICAL INCORPORATED | 2003-07-01 | — | — | US | claimed |
| US-20020102297-A1 | Macromolecule-lipid complexes and methods for making and using | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-08-01 | — | — | US | claimed |
| US-6235310-B1 | LIPID COMPLEXES AND CATIONIC LIPIDS, DIMETHYLDIOCTADECYL AMMONIUM BROMIDE AND AMMONIUM COMPOUNDS WITH NEUTRAL LIPIDS OF DIALKANOYLGLYCERO-3-PHOSPHOETHANOLAMINE | VALENTIS, INC. | 2001-05-22 | — | — | US | claimed |